Close
Achema middle east
swop processing & packaging

Amgen To Present At The Credit Suisse 25th Annual Healthcare Conference

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amgen will present at the Credit Suisse 25th Annual Healthcare Conference at 9 a.m. MT on Tuesday, Nov. 8, 2016, in Scottsdale, Ariz. David W. Meline, executive vice president and chief financial officer at Amgen, and Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will present at the conference.

Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.For more information, visit www.amgen.com.

CONTACT: Amgen,
Thousand Oaks
Kristen Davis,
805-447-3008 (media)

Kristen Neese,
805-313-8267 (media)

Arvind Sood,
805-447-1060 (investors)

Latest stories

Related stories

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »